The role of self-monitoring of blood glucose during the treatment of type 2 diabetes with medications targeting postprandial hyperglycemia

Southern Medical Journal

Volumn 100, Issue 11, 2007, Pages 1123-1131

  Choe, Charles ^a   Edelman, Steven V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes; Drug therapy; Macrovascular complications; Postprandial hyperglycemia; Self monitoring of blood glucose

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ASPARTAME; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PRAMLINTIDE; REPAGLINIDE; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; VOGLIBOSE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET RESTRICTION; DIET THERAPY; EXERCISE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE PERSONNEL; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; REVIEW; SELF MONITORING;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; POSTPRANDIAL PERIOD; RISK FACTORS;

EID: 35948932214     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000286751.78656.45     Document Type: Review

References (76)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
2. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
4. Stratton IM, Adler AI, Neil HAW, et al, on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
5. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006;29:531-537.
6. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44:968-983.
7. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:178-181.
8. Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Ther 2003;5:19-26.
9. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-269.
10. Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care 2001;24:1734-1738.
11. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
12. 1c. Diabetes Care 2003;26:881-885.
13. Beebe CA. Self blood glucose monitoring: an adjunct to dietary and insulin management of the patient with diabetes. J Am Diet Assoc 1987;87:61-65.
14. Sarol JN Jr, Nicodemus NA Jr, Tan KM, Grava MB. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966 -2004). Curr Med Res Opin 2005;21:173-183.
15. Welschen LMC, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 2005;28:1510-1517.
16. Martin S, Schneider B, Heinemann L, et al, for the ROSSO Study Group. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 2006;49:271-278.
17. Karter AJ, Ferrara A, Darbinian JA, et al. Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. Diabetes Care 2000;23:477-483.
18. Vincze G, Barner JC, Lopez D. Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes. Diabetes Educ 2004;30:112-125.
19. Phillips LS, Branch WT Jr, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135:825-834.
20. Tuttleman M, Lipsett L, Harris MI. Attitudes and behaviors of primary care physicians regarding tight control of blood glucose in IDDM patients. Diabetes Care 1993;16:765-772.
21. Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia. 2003;46(suppl 1):M44-M50.
22. Sudhir R, Mohan V. Postprandial hyperglycemia in patients with type 2 diabetes mellitus [review]. Treat Endocrinol 2002;1:105-116.
23. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence [review]. Diabetologia 2001;44:2107-2114.
24. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54:1-7.
25. de Vegt F, Dekker JM, Ruhé HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-931.
26. Lowe LP, Liu K, Greenland P, et al. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997;20:163-169.
27. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1987;36:689-692.
28. Hanefeld M, Fischer S, Julius U, et al, for the DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583.
29. DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
30. 1C level. Diabetes Care 2000;23:1830-1834.
31. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care 2007;30(Suppl 1):S4-S41.
32. American College of Endocrinology. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract 2002;8(suppl 1):5-11.
33. Esposito K, Giugliano D, Nappo F, Marfella R, for the Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214-219.
34. Chiasson J-L, Josse RG, Gomis R, et al, for the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-494.
35. Parkin CG, Brooks N. Is postprandial glucose control important? Is it practical in primary care settings? Clin Diabetes 2002;20:71-76.
36. Monnier L, Colette C, Lapinski H, Boniface H. Self-monitoring of blood glucose in diabetic patients: from the least common denominator to the greatest common multiple [review]. Diabetes Metab 2004;30:113-119.
37. Schwedes U, Siebolds M, Mertes G, for the SMBG Study Group. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care 2002;25:1928-1932.
38. Davidson MB, Castellanos M, Kain D, Duran P. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. Am J Med 2005;118:422-425.
39. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28(suppl 1):S4-S36.
40. Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. Acta Diabetol 1994;31:215-219.
41. Feher MD, Bailey CJ. Reclassifying insulins. Br J Diabetes Vasc Dis 2004;4:39-42.
42. Rabasa-Lhoret R, Garon J, Langelier H, et al. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen. Diabetes Care 1999;22:667-673.
43. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia [review]. Arch Intern Med 2003;163:1306-1316.
44. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M, on behalf of the Exubera Phase III Study Group. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006;29:1282-1287.
45. Feinglos MN, Thacker CH, English J, et al. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997;20:1539-1542.
46. Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004;21:171-175.
47. 1c. Diabetes Care 2000;23:1236-1241.
48. Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:304-312.
49. Apidra [package insert]. Kansas City, Mo: Aventis Pharmaceuticals Inc.; 2005.
50. van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005;28:154-163.
51. Rosenstock J, Hassman DR, Madder RD, et al, for the Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27:1265-1270.
52. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119-124.
53. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660-1665.
54. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second β-cell hormone. Diabetes Technol Ther 2002;4:175-189.
55. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003;26:784-790.
56. Maggs DG, Fineman M, Kornstein J, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev 2004;20:55-60.
57. Levetan C, Want LL, Weyer C, et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 2003;26:1-8.
58. Gallwitz B. Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass. Diabetes Technol Ther 2005;7:651-657.
59. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-3089.
60. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100.
61. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091.
62. Feinglos MN, Saad MF, Pi-Sunyer FX, et al, on behalf of the Liraglutide Dose-Response Study Group.. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005;22:1016-1023.
63. Baggio LL, Drucker DJ: Incretin hormones in the treatment of type 2 diabetes: therapeutic applications of DPP-IV inhibitors. Medscape Diabetes & Endocrinology 2006;8.
64. Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-1940.
65. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692-698.
66. Scott R, Herman G, Zhao P, Chen X: Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes (T2D) [abstract 41-OR]. Diabetes 2005;54:A10.
67. Herman G, Hanefeld M, Wu M, et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes [abstract 541-P]. Diabetes 2005;54:A134.
68. Humalog Mix75/25 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2005.
69. NovoLog [package insert]. Princeton, NJ: Novo Nordisk Inc; 2005.
70. Precose [package insert]. West Haven, CT: Bayer Pharmaceuticals Corporation; 2004.
71. Exubera [package insert]. New York, NY: Pfizer Labs; 2006.
72. Glyset [package insert]. Leverkusen, Germany: Bayer HealthCare AG; 2004.
73. Prandin [package insert]. Princeton, NJ: Novo Nordisk Inc; 2006.
74. Starlix [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2004.
75. Symlin [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2005.
76. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2005.